Deal Watch: Zymeworks Adds Daiichi To List Of Partners In I-O Cross Collaboration
Amgen gets into RNAi for cardiovascular indications with Arrowhead deal. Lilly and J&J out-license preclinical candidates, for epilepsy and cancer respectively, to smaller firms Cerecor and Tracon.
You may also be interested in...
Novartis will take over development and commercialization of antisense candidate TQJ230 under rights it obtained in a 2017 agreement. Morphic and Janssen will collaborate on oral integrin inhibitors.
Celgene reworks its collaboration with Abide, dropping its buyout option. Roivant gains Chinese rights to anti-infective lemafulin and adds a fifth candidate to Dermavant's pipeline, while pSivida acquires Icon and FDA-approved Dexycu for cataract surgery inflammation.
Amgen is validating targets through the deCODE Genetics investment it made five years and moving drugs into the clinic. It's one of multiple technologies – along with its BiTE and oncolytic virus platforms – that R&D head Sean Harper said is starting to bear fruit for the company.